- Investing.com
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Analyst Outlook | Learn about the bullish sentiment surrounding EWTX, with price targets ranging from $30 to $56, reflecting substantial upside potential |
Market Potential | Delve into Edgewise's positioning in the lucrative rare disease market, addressing significant unmet needs in HCM and muscular dystrophy |
Clinical Milestones | Explore the company's catalyst-rich 2025, featuring crucial data readouts for EDG-7500 and sevasemten in muscular dystrophy programs |
Novel Therapies | Edgewise Therapeutics develops innovative treatments for rare muscle disorders, with lead candidate EDG-7500 in clinical trials for hypertrophic cardiomyopathy |
Metrics to compare | EWTX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEWTXPeersSector | |
---|---|---|---|---|
P/E Ratio | −19.4x | −1.3x | −0.7x | |
PEG Ratio | 5.25 | −0.01 | 0.00 | |
Price / Book | 4.9x | 0.7x | 2.6x | |
Price / LTM Sales | - | 5.2x | 3.1x | |
Upside (Analyst Target) | 96.9% | 417.9% | 47.6% | |
Fair Value Upside | Unlock | 13.3% | 7.7% | Unlock |